NASDAQ:RGLS

Regulus Therapeutics News Headlines

$0.23

+0.02 (+9.70%)

(As of 05/20/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.20
▼
$0.24
50-Day Range: $0.16
▼
$0.34
52-Week Range: $0.16
▼
$1.48

Volume: 1.44 million shs
Average Volume: 4.26 million shs
Market Capitalization: $33.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 2.21

Get Regulus Therapeutics News Delivered to You Automatically

Media Mentions By Week

Regulus Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RGLS
News Sentiment
▼
0.45

0.30
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RGLS Articles
This Week
▼
2

1
▲
RGLS Articles
Average Week

Regulus Therapeutics (NASDAQ:RGLS) News Headlines Today

Source

Source	Headline
	Regulus Therapeutics (NASDAQ:RGLS) Lifted to "Buy" at Zacks Investment Research americanbankingnews.com - May 16 at 3:20 AM
	Regulus Therapeutics (NASDAQ:RGLS) Receives Overweight Rating from Cantor Fitzgerald americanbankingnews.com - May 13 at 3:26 AM
	Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q1 2022 Results - Earnings Call Transcript seekingalpha.com - May 13 at 3:18 AM
	Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates finance.yahoo.com - May 13 at 3:18 AM
	Regulus Therapeutics Inc. (NASDAQ:RGLS) to Post FY2022 Earnings of ($0.25) Per Share, Cantor Fitzgerald Forecasts americanbankingnews.com - May 13 at 2:50 AM
	StockNews.com Begins Coverage on Regulus Therapeutics (NASDAQ:RGLS) americanbankingnews.com - May 13 at 1:30 AM
	Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug finance.yahoo.com - May 12 at 2:31 PM
	Regulus spikes as FDA clears trial for kidney disease candidate seekingalpha.com - May 11 at 2:38 PM
	FDA Clears Regulus Therapeutics' IND for RGLS8429 In Autosomal Dominant Polycystic Kidney Disease (ADPKD) benzinga.com - May 11 at 9:38 AM
	Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) finance.yahoo.com - May 11 at 9:38 AM
	Regulus Therapeutics (RGLS) Scheduled to Post Quarterly Earnings on Thursday americanbankingnews.com - May 10 at 4:42 AM

	Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call finance.yahoo.com - May 5 at 8:59 PM
	Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com americanbankingnews.com - May 5 at 1:44 AM
	Regulus Therapeutics Inc. (RGLS) finance.yahoo.com - May 3 at 8:26 PM
	RGLS Regulus Therapeutics Inc. seekingalpha.com - April 30 at 6:53 PM
	Regulus Starts Preclinical Studies In ALS Under Pact With Brigham and Women's Hospital finance.yahoo.com - March 24 at 8:38 PM
	Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital finance.yahoo.com - March 24 at 10:33 AM
	Regulus Therapeutics GAAP EPS of -$0.07 seekingalpha.com - March 12 at 10:00 PM
	Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates finance.yahoo.com - March 10 at 6:13 PM
	Regulus Therapeutics Q4 2021 Earnings Preview seekingalpha.com - March 9 at 9:43 PM
	Regulus Therapeutics's Earnings: A Preview benzinga.com - March 9 at 4:06 PM
	Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome finance.yahoo.com - February 24 at 1:09 PM
	Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference finance.yahoo.com - February 10 at 5:13 PM
	Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? finance.yahoo.com - January 26 at 1:44 PM
	Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder finance.yahoo.com - January 21 at 12:18 PM
	Regulus Therapeutics Says FDA Meeting Successful, Shares Rise 6% marketwatch.com - January 20 at 6:32 PM
	Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429 finance.yahoo.com - January 20 at 6:32 PM
	Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development finance.yahoo.com - December 3 at 9:56 AM
	Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit finance.yahoo.com - December 1 at 9:46 AM
	Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity finance.yahoo.com - November 30 at 6:55 PM
	Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com - November 10 at 11:07 PM
	Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates finance.yahoo.com - November 10 at 6:07 PM
	Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call finance.yahoo.com - November 3 at 8:24 PM
	Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for finance.yahoo.com - October 28 at 9:05 PM

	How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More msn.com - October 18 at 9:53 PM
	Regulus Therapeutics Reports Strategic Prioritization Of RGLS8429 Candidate For Treatment Of Autosomal Dominant Polycystic Kidney Disease benzinga.com - October 14 at 1:24 AM
	Regulus Therapeutics to Prioritize RGLS8429 Treatment for Certain Kidney Disease marketwatch.com - October 14 at 1:24 AM
	BRIEF-Regulus Therapeutics Announces Strategic Prioritization Of Polycystic Kidney Disease Treatment msn.com - October 12 at 6:19 PM
	Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease finance.yahoo.com - October 12 at 6:19 PM
	Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science finance.yahoo.com - September 30 at 6:58 PM
	Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference finance.yahoo.com - September 9 at 6:23 PM
	Recap: Regulus Therapeutics Q2 Earnings benzinga.com - August 12 at 10:58 PM
	Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates finance.yahoo.com - August 10 at 11:11 PM
	Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call finance.yahoo.com - August 3 at 8:16 PM
	Regulus Therapeutics Inc. Common Stock (RGLS) nasdaq.com - July 24 at 9:43 PM
	Is Regulus Therapeutics Inc (RGLS) A Good Stock To Buy? finance.yahoo.com - June 30 at 1:36 PM
	Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 finance.yahoo.com - June 25 at 8:08 AM
	Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 finance.yahoo.com - June 21 at 8:27 AM
	Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't? finance.yahoo.com - June 11 at 9:43 AM
	Is Regulus Therapeutics (NASDAQ:RGLS) Using Too Much Debt? nasdaq.com - June 9 at 2:20 PM

Get Regulus Therapeutics News Delivered to You Automatically

This page was last updated on 5/21/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources